Navigation Links
NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
Date:5/16/2012

ver a 24-hour period compared to placebo with a fast onset of action at first dose, as well as improving exercise endurance. It was submitted for regulatory approval in Europe in Q3 2011 and Japan in Q4 2011, and expected US filing is in the beginning of 2014. NVA237 was licensed to Novartis in April 2005 by Sosei and our co-development partner Vectura.

Indacaterol (Onbrez® Breezhaler®) is Novartis' once daily long acting beta2-agonist (LABA). Novartis received European regulatory approval for 150 mcg and 300 mcg once-daily doses, under the brand name Onbrez® Breezhaler® in November 2009. In July 2011, Novartis announced approval of the 75 mcg once-daily dose in the US under the brand name Arcapta™ Neohaler™, and of the 150 mcg once-daily dose in Japan under the brand name Onbrez® Inhalation Capsules.

QVA149 (indacaterol 110 mcg/glycopyrronium bromide 50 mcg) is an investigational inhaled, once-daily, fixed dose combination of the long acting beta2-agonist (LABA) indacaterol, and the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide (NVA237). The first four QVA149 Phase III studies in the treatment of COPD all met their primary endpoints. The results of the SHINE, BRIGHT, ENLIGHTEN and ILLUMINATE studies, which are key components of the IGNITE program, demonstrate the potential of QVA149 in the treatment of COPD. Filing for QVA149 in Europe is expected in Q4 2012.

About COPD

COPD is a progressive disease associated mainly with tobacco smoking, air pollution or occupational exposure, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. It affects an estimated 210 million people worldwide[1]and is predicted to be the third leading cause of death by 2020[2]. Although COPD is often thought of as a disea
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
2. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
3. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
4. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
7. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
9. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
10. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014  The acceptance of two abstracts ... Global Congress demonstrates continued interest in the Eclipse ... bowel control. One of the abstracts, presented by ... Chief of Urogynecology and Reconstructive Pelvic Surgery at ... for Best Written Abstract on Urogynecology/Pelvic Floor Disorders/Vaginal ...
(Date:11/21/2014)... Nov. 20, 2014 Oxis International, Inc. (OXIS) (OXI.PA) ... election of Anthony J. Cataldo as Chief Executive ... Effective November 19, 2014, Ken Eaton resigned his ... of Directors of Oxis International, Inc. to pursue new opportunities. ... named Chief Executive Officer of Oxis International, Inc. Mr. Cataldo ...
(Date:11/18/2014)... , Nov. 18, 2014  NxStage ® ... a leading manufacturer of innovative dialysis products ... Streamline® Express dialyzer for the in-center, hemodialysis ... set, which is designed to reduce the amount ... reduce the number of touch point contamination sites.  ...
Breaking Medicine Technology:LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set 2
(Date:11/21/2014)... -- Seeking to make it tougher for people to ... on Thursday approved a new hydrocodone tablet that,s designed ... by the brand name Vicodin -- is a powerful ... in dangerous addictions across the United States. The ... is an extended-release tablet to treat pain severe enough ...
(Date:11/21/2014)... they,ve mapped the genome -- the genetic "blueprint" -- of ... it might help others with this very rare infection. ... , the tapeworm was removed from the brain of a ... so rare worldwide and completely unexpected in this country that ... pulled out from the brain," study lead author Hayley Bennett, ...
(Date:11/21/2014)... November 21, 2014 Center for Autism ... titled “Massachusetts Insurance Funding for Autism Workshops” to help ... their way through the insurance coverage process. Parents ... law and the most effective ways to access coverage. ... 4 from 6-8:00 p.m. at 331 Montvale Ave., 5th ...
(Date:11/21/2014)... 21, 2014 Big Bud Farms announced ... episode of Innovations with Ed Begley Jr., airing via ... TBA. , Big Bud Farms, growers of legal medical ... and utilization of medical marijuana. , This segment of ... wide variety of products for medicating. Viewers will learn ...
(Date:11/21/2014)... 2014 Launched today on the iTunes ... all-in-one senior care coordination tool designed to make tracking ... and intuitive for family members and caregivers (e.g. physicians ... the family caregiver or home health aide providing care ... data, medical records, goals, schedules, and even final plans ...
Breaking Medicine News(10 mins):Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3Health News:Ick! Tapeworm Infecting Man's Brain Yields Genetic Secrets 2Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2Health News:Big Bud Farms to be Featured in Upcoming Episode of Innovations with Ed Begley Jr. 2Health News:Comprehensive Senior Care Application Launched on Apple App Store 2
... LOS ANGELES, Nov. 8 Response Genetics, Inc.,(Nasdaq: ... development of molecular,diagnostic tests for cancer, today announced ... financial results in a press release on,Wednesday, November ... Response Genetics, Inc. ("RGI") is engaged in the ...
... EMPLOYERS(R) (NYSE: EIG ),a leading ... a,new partnership with the California Restaurant Association ... compensation insurance with a,special CRA membership discount. ... http://www.newscom.com/cgi-bin/prnh/20061030/LAM128LOGO ) "We are enthusiastic ...
... 8 DATATRAK International,Inc. (Nasdaq: DATA ), a ... the clinical trials industry, today reported its,operating results for ... For the three months ended September 30, 2007, ... net loss of $(3,506,000), or $(0.26),per share on a ...
... Resources on Partnership to Develop Rapid Molecular ... Tests for Healthcare-Associated Infections -, SAN DIEGO, Nov. 8 ... informed the Company it no longer intends to,fund the companies, ... The companies expect to formally terminate the,collaboration in the coming ...
... Approve Sale of Nabi ... Biologics to Biotest, ... today announced its third quarter,financial results. The company recorded a net ... September 29, 2007, which included,$7.5 million, or $0.12 per share, of ...
... Hispanic youth report better dental health habits than their non-Hispanic ... researchers at Columbia University Mailman School of Public Health. ... the Journal of Health Care for the Poor and Underserved, ... community in America. , The study, a snapshot of more ...
Cached Medicine News:Health News:Response Genetics to Announce Third Quarter 2007 Financial Results on Wednesday, November 14, 2007 2Health News:California Restaurant Association Chooses EMPLOYERS(R) as its New Provider of Choice for Members' Workers' Compensation Insurance Needs 2Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 2Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 3Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 4Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 5Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 6Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 7Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 8Health News:3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration 2Health News:3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration 3Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 2Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 3Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 4Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 5Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 6Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 7Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 8Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 9Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 10Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 11Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 12Health News:Study of minority New York City youth finds unequal burden of poor dental health 2
... and fabric specialty drapes for ... Steri-Drape absorbent prevention fabric creates ... strike-through reducing the need for ... Pack, Op tape, Hand towels, ...
... The table top design takes into ... and creates a flexible working environment for ... the alphamaxx can be matched exactly to ... top slide capability creates superior access for ...
... DePuy Mitek is the Market leader ... With ORTHOCORD Suture, DePuy Mitek has developed ... arthroscopic and open shoulder repair. ORTHOCORD Suture ... suture on the market. Most importantly, ORTHOCORD ...
... Now you can ... tactile sensitivity of the ... Free surgical gloves on ... Free gloves provide the ...
Medicine Products: